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Milestones in laboratory procedures and 
techniques
When I left England in 1969, hemagglutination was done by sedimentation. In New York, I was intro-duced to centrifugation as a method to speed the 
process. Both approaches accomplished similar goals, but 
one was more time efficient. Use of other techniques, such 
as Western immunoblotting, cloning genes, and polymerase 
chain reaction, made it possible to gain much knowledge 
about blood group antigens.
Immunohematology Beginnings
 In 1975, Sandy Ellisor and I from Central California 
Region of the American Red Cross (ARC) and Helen Glid-
den from ARC Headquarters volunteered to co-edit the first 
American Red Cross Reference Laboratory Newsletter. 
The purpose of this newsletter, which was for the technolo-
gists and by the technologists, was to share techniques and 
technical tips, educate, and mentor in technical writing. The 
first year (1976), the newsletter was low-tech; it was simply 
photocopied. That year, the ARC Reference Laboratory 
Committee ran a competition and by popular vote the news-
letter was renamed the Red Cell Free Press.  And to improve 
its appearance it was printed. This informal newsletter was 
published for 8 years, until in 1984 it evolved into Immuno-
hematology under the able editorship of Delores Mallory.1 
During the 25-year life of Immunohematology, techniques 
evolved that allowed the gathering of an amazing amount 
of knowledge about blood groups and the membrane com-
ponents on which they are carried.  Despite this evolution, 
to this day we still mainly rely on hemagglutination (direct 
and indirect) for detection and identification of antibodies 
to blood group antigens and for testing for incompatibility. 
This amazing technique is hard to beat in terms of sensitivi-
ty and specificity that are appropriate for safe transfusions.
Early Immunohematology Testing Practices
 In the era before the ARC Newsletter, it was common-
place to perform excessive testing (e.g., testing at room 
temperature, use of enzyme-treated RBCs at temperatures 
below 37ºC, absorbing eluates from autoimmune hemo-
lytic anemia cases, and performing minor crossmatches) 
on a single blood sample. Fortunately, Eloise Giblett in the 
early 1960s advocated stopping unnecessary testing; she 
believed testing should be done as close to physiologic con-
ditions as possible, i.e., testing at 37ºC using plasma-sus-
pended RBCs. Her reasoning was scholarly and logical and 
changed the way testing was (and is) done. Giblett’s labora-
tory used plasma-suspended RBCs, which neutralized most 
antibodies to Lewis and Ch/Rg antigens and thus they did 
not spend time identifying these clinically insignificant an-
tibodies. Abandonment of unnecessary testing dramatically 
improved the efficiency of testing by manual hemagglutina-
tion and did not have a noticeable negative impact on the 
efficacy of transfusion. Other changes, which occurred with 
the same goal, include using anti-IgG instead of the broad-
spectrum reagent in routine antiglobulin tests, eliminating 
the routine direct antiglobulin test (DAT), and not prepar-
ing eluates from all samples whose RBCs were positive in 
the DAT.
 Also in the late 1970s, an extraordinary number of 
crossmatches were performed. Indeed, the number was ex-
cessive. The concepts of a “type and screen”2 and a “maxi-
mum surgical blood order schedule”3 were introduced. 
These approaches were quickly adopted, and they reduced 
not only the number of crossmatches but also the number 
of RBC components reserved for a particular patient. Soon 
after, the suggestion to drop the antiglobulin crossmatch 
for patients who had a negative antibody screen was un-
leashed.4–6 Despite concerns that antibodies to antigens 
not expressed on screening RBCs (e.g., anti-Wra) would 
be missed, this practice is now commonplace. Indeed, the 
physical immediate-spin crossmatch is now frequently re-
placed by a computer crossmatch.7
Use of Enhancement Reagents and Nonserologic 
Techniques
 Old standby techniques such as saline and albumin fell 
from favor and were largely replaced by low-ionic-strength 
solution (LISS) methods in the mid-1970s8 and by LISS-ad-
ditive solutions shortly thereafter. LISS rapidly gained popu-
larity because it simultaneously reduced incubation time and 
increased sensitivity. In 1984, the same year that the first vol-
ume of Immunohematology appeared, a solid-phase adher-
ence assay for detection of antibody-antigen reactions was 
introduced. For a review of this technology, see Beck et al.9 
Subsequently, other techniques were reported and quickly 
became popular; two examples are the use of polyethylene 
glycol (PEG) as a potentiator of antibody-antigen reactions 
in 198710 and the column agglutination technology, using 
a gel as the support medium, in 1990.11 Automated assays 
based on hemagglutination and manual or automated solid-
phase adherence assays are now in use, but they have not 
replaced hemagglutination tests in tubes in many settings.
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 Many reagents became commercially available, and as 
compliance requirements became more stringent, labora-
tories reduced the number of reagents they prepared in-
house. Safety concerns prompted many changes. Favorite 
methods fell from grace, such as the use of ether—as a re-
sult of concerns about its low flash point. Also, teratogenic, 
carcinogenic, and neurotoxic chemicals became less read-
ily available. Awareness of the potential hazards of work-
ing with certain chemicals and with blood samples that may 
contain various pathogens led to the strict requirement to 
wear personal protective equipment such as gloves, labora-
tory coats, eye protection, and closed-toed shoes. The long-
standing practice of drinking, eating, and smoking in the 
laboratory was abolished.
 The value of proteolytic enzymes, notably ficin, for en-
hancing the reactivity of some antibody-antigen reactions 
while weakening or ablating others has been appreciated 
for many years.12 Other red cell modifications such as di-
thiothreitol (DTT), trypsin, and α-chymotrypsin13 were in-
troduced. However, it took some time before the full power 
of using the combination (i.e., testing RBCs treated with 
ficin or papain, trypsin, α-chymotrypsin, or DTT) of these 
methods to aid in antibody identification was appreciated. 
Although classic antibody identification approaches (and 
appropriate controls) are still necessary to name an anti-
body specificity positively, a system of parallel testing of the 
same RBCs untreated and treated with different reagents 
provides a valuable tool in helping to guide us in the right di-
rection, without requiring a vast library of rare reagents.14,15 
When using enzymes for this purpose, it is important 
to include a negative (or auto) control, as a proportion of 
human sera contain antibodies that attach to RBCs treated 
with a proteolytic enzyme.
Use of Monoclonal Reagents
 For many years, we were dependent on polyclonal anti-
bodies from human or rabbit sera or from plant lectins such 
as Vicia graminea, Ulex europeaus, and Dolichos biflorus 
for blood grouping reagents. In 1975, Köhler and Milstein 
described a technique to fuse murine myeloma cells with 
antibody-secreting B cells to produce monoclonal antibod-
ies.16 This technique was embraced, and monoclonal an-
tibodies were produced to highly immunogenic antigens 
such as to carbohydrate human blood group antigens (A 
and B, Lewis, and P1) and high copy number glycoproteins 
(M, N).17 It took several years before human B cells were 
used in place of mouse cells. With this advancement came 
the production of monoclonal anti-D in 1983.19 Monoclo-
nal antibodies with other specificities have been made in 
the last 25 years.19 They are now the predominant source 
of typing reagents, and three international workshops have 
been held to study reaction characteristics of numerous 
monoclonal antibodies. Monoclonal antibodies have had 
a major impact on our ability to define variant RBCs, espe-
cially partial D antigens, and to optimize techniques such 
as flow cytometry and Western immunoblotting. Molecular 
biology techniques have made it possible to convert murine 
IgG monoclonal antibodies to human IgG or directly agglu-
tinating IgM.20
Techniques to Predict Clinical Significance of Anti-
bodies
 Hemagglutination detects antibodies, but in itself does 
not predict their clinical significance. Criteria such as titer, 
phase of reactivity, Ig class, IgG subclass, and specificity 
(and the historic knowledge of the clinical significance of an 
antibody in other patients) are useful indicators but are not 
unequivocally good predictors of clinical significance. The 
monocyte monolayer assay (MMA) is as close to conditions 
in vivo as is possible to establish in vitro and provides in-
sight into the potential clinical significance of an antibody. 
It has been applied to predicting the clinical relevance of 
antibodies in transfusion21 and hemolytic disease of the 
newborn,22–24 but is a highly specialized and technically dif-
ficult test that belongs in a small number of laboratories. 
Another technique, flow cytometry, has been used to detect 
minor RBC populations in a fetal maternal hemorrhage and 
to follow the survival of transfused RBCs,25,26 to determine 
the dosage of a blood group antigen on RBCs,27 and quanti-
tation of RBC-bound IgG.28
 Numerous techniques have been used to identify al-
loantibodies underlying autoantibodies.29–32 All are time-
consuming, as are methods to separate patient RBCs from 
those of transfused donor RBCs so that the patient’s RBCs 
can be phenotyped.33 Washing peripheral blood RBCs from 
transfused patients with sickle cell disease with a hypoton-
ic solution is a simple and clever technique to obtain the 
patient’s RBCs for typing by hemagglutination.34 Although 
these techniques have value, they also have limitations.
 
Molecular Testing
 Although hemagglutination remains the predominant 
test for detecting antibody-antigen interactions, unrelated 
techniques have provided insight into RBC components 
that carry blood group antigens. In the decade before 
Immunohematology first appeared, the Western immuno-
blotting method was used extensively to study characteris-
tics of components carrying blood groups. This approach, 
together with cloning and sequencing of the genes encoding 
blood group antigens,35 has revealed sequence homology to 
known proteins in other cell types and provided insights 
into the structure and function of the RBC membrane com-
ponents carrying blood groups (Table 1).36
 The cloning and sequencing of genes laid the ground-
work for analysis of many alleles encoding variant blood 
group antigens and phenotypes and, thus, our ability to test 
DNA by the polymerase chain reaction (PCR) to predict a 
blood group. Subsequent manufacturing of machines to 
automatically perform PCR amplification made it possible 
to perform this technique in a clinical laboratory setting. 
PCR-based tests on DNA to predict a blood type have several 
applications that provide a substitute for phenotyping.37 The 
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presence of donor RBCs in a patient’s blood sample or IgG 
on RBCs (positive DAT) does not interfere with the tests. 
RBCs are not required to type a fetus at risk for hemolytic 
disease of the newborn (Table 2). Thus, during the life of 
Immunohematology, we have had a reversal of phenotype 
and genotype. We used to phenotype RBCs to predict the 
genotype; now we test DNA to predict the phenotype, both 
with the understanding that variant and null alleles exist.
 If high-throughput platforms were inexpensive enough, 
DNA testing and prediction of antigen types could be used 
as a screening method to increase antigen-negative inven-
tories. Where antisera are available, negative DNA screening 
results could be confirmed by hemagglutination methods, 
thereby conserving reagents. When antisera are not avail-
able, (e.g., anti-Dob, anti-Hy) the predicted type is often 
more reliable than the crossmatch. The availability of 
increased inventories of RBC components with various 
combinations of antigen-negativity would make it possible 
to more precisely match a patient’s phenotype, before the 
patient was immunized. The technique could be used to es-
sentially eliminate repetitive time-consuming techniques 
needed to identify underlying alloantibodies in cases of 
warm autoimmune hemolytic anemia and antibodies to 
high-prevalence antigens.
 Modifications of classic hemagglutination, which in-
creased its sensitivity and specificity and reduced the time 
it takes to perform the test, have contributed to the safe 
transfusion practice as we know it today. Although West-
ern immunoblotting and PCR-based assays have led to an 
understanding of the function and structure of RBC membrane 
components carrying blood groups, hemagglutination 
remains the workhorse of immunohematology testing. 
However, despite all our advances, errors in identification 
and clerical errors are still the big problem, 
and ABO incompatibility remains a primary 
cause of preventable transfusion-related fatali-
ties.38–40 Approximately half of the errors occur 
when blood is transfused to the wrong patient. 
Sample collection error, i.e., drawing blood 
from the wrong patient or mislabeling the 
sample, is also responsible for the blood being 
transfused to the wrong patient.41 Hemaggluti-
nation in tubes does not require sophisticated 
equipment. It is simple, inexpensive (although 
antibodies are becoming expensive and tech-
nologist costs constantly rise), sensitive, spe-
cific, and reproducible. It remains the basic 
method for detecting reactions between RBCs 
and antibodies.
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Table 2. Potential uses of DNA-based assays
To type patients who have been recently transfused
To identify a fetus at risk for hemolytic disease of the newborn
To type patients whose RBCs are coated with immunoglobulin (positive 
DAT)
To type patients with AIHA* to select antigen-negative RBCs for absorp-
tion of autoantibodies when searching for underlying alloantibodies
To type donors, including mass screening for antigen-negative donors, 
when appropriate antisera are not readily available
To type donors for use on antibody identification panels when antisera are 
not available
To type patients who have an antigen that is expressed weakly on RBCs
To resolve blood group A, B, and D discrepancies
To study unusual and novel serologic reactions
*AIHA = autoimmune hemolytic anemia
Table 1. Structure and function of RBC membrance components 
carrying blood group antigens
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